Skip Nav Destination
Issues
1 November 2013
-
Cover Image
Cover Image
Strohecker and colleagues found that deletion of the essential autophagy gene Atg7 initially induced oxidative stress and accelerated the formation of BrafV600E-driven lung tumors but eventually slowed tumor growth and prolonged survival. Atg7 deficiency led to an accumulation of morphologically and functionally defective mitochondria in BrafV600E-driven lung tumors and rendered tumor cells dependent on exogenously supplied glutamine for survival. BrafV600E-driven tumors may therefore become addicted to autophagy to sustain cell survival and proper mitochondrial function through the clearance of damaged organelles and recycling of metabolites for biosynthesis, and may thus be sensitive to autophagy inhibitors. For details, please see the article by Strohecker and colleagues on page 1272. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
In the Spotlight
Review
Research Briefs
Author Choice
Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
Violeta Serra; Ana Vivancos; Xose S. Puente; Enriqueta Felip; Daniel Silberschmidt; Ginevra Caratù; Josep-Lluís Parra; Leticia De Mattos-Arruda; Judit Grueso; Javier Hernández-Losa; Joaquín Arribas; Ludmila Prudkin; Paolo Nuciforo; Maurizio Scaltriti; Joan Seoane; José Baselga
Author Choice
Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
William R. Polkinghorn; Joel S. Parker; Man X. Lee; Elizabeth M. Kass; Daniel E. Spratt; Phillip J. Iaquinta; Vivek K. Arora; Wei-Feng Yen; Ling Cai; Deyou Zheng; Brett S. Carver; Yu Chen; Philip A. Watson; Neel P. Shah; Sho Fujisawa; Alexander G. Goglia; Anuradha Gopalan; Haley Hieronymus; John Wongvipat; Peter T. Scardino; Michael J. Zelefsky; Maria Jasin; Jayanta Chaudhuri; Simon N. Powell; Charles L. Sawyers
Research Articles
Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
Masato Nishimura; Eun-Jung Jung; Maitri Y. Shah; Chunhua Lu; Riccardo Spizzo; Masayoshi Shimizu; Hee Dong Han; Cristina Ivan; Simona Rossi; Xinna Zhang; Milena S. Nicoloso; Sherry Y. Wu; Maria Ines Almeida; Justin Bottsford-Miller; Chad V. Pecot; Behrouz Zand; Koji Matsuo; Mian M. Shahzad; Nicholas B. Jennings; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K. Sood; George A. Calin
News in Brief
News in Depth
Research Watch
Apoptosis
Autophagy
Breast Cancer
Cell Cycle
Clinical Trials
DNA Damage
Epigenetics
Genomic Instability
Glioma
Immune Evasion
Immunotherapy
Inflammation
Leukemia
Mitosis
Preclinical Studies
Prostate Cancer
Signaling
Stem Cells
Transcription Factors
Tumor Suppressors
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.